scispace - formally typeset
R

Rafael Molina

Researcher at University of Granada

Publications -  398
Citations -  11970

Rafael Molina is an academic researcher from University of Granada. The author has contributed to research in topics: Image restoration & Iterative reconstruction. The author has an hindex of 52, co-authored 381 publications receiving 10765 citations. Previous affiliations of Rafael Molina include Intel & Northwestern University.

Papers
More filters
Journal ArticleDOI

High-resolution images from low-resolution compressed video

TL;DR: This survey surveys the field of super resolution (SR) processing for compressed video and develops and presents all techniques within the Bayesian framework, and surveys models for the acquisition and compression systems.
Journal ArticleDOI

ProGRP: a new biomarker for small cell lung cancer.

TL;DR: Preliminary studies suggest ProGRP will have utility in conjunction with NSE in monitoring the therapy of established SCLC, and is a more sensitive biomarker than is neuron-specific enolase for SCLP, but thus far has not been found in multivariate analysis to have independent prognostic significance.
Journal ArticleDOI

Bayesian resolution enhancement of compressed video

TL;DR: This paper considers the impact of video compression on the super-resolution task, and utilizes the Bayesian framework to incorporate information from Hybrid motion-compensation and transform coding schemes to fuse thesuper-resolution and post-processing problems.
Journal ArticleDOI

Audiovisual Fusion: Challenges and New Approaches

TL;DR: This review will address issues in AV fusion in the context of AV speech processing, and especially speech recognition, where one of the issues is that the modalities both interact but also sometimes appear to desynchronize from each other.
Journal ArticleDOI

Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.

TL;DR: CEA and CA 15.3 are useful tools for early diagnosis of metastases, mainly in those patients with ER+ or PR+ tumors and in patients that were negative for these receptors in the primary tumor.